SBIR Technology Transfer

(R43/R44 Clinical Trial Not Allowed)

Notice of Special Interest (NOSI): NOT-NS-22-017

Receipt Date: January 5, 2022

William Bozza, Ph.D.

Contact William Bozza to learn more about this program.

Expires on: January 5, 2025

This targeted funding opportunity aims to help move commercially-viable technologies from the NIH Intramural Program to the marketplace. Small businesses are encouraged to submit applications that further develop available technologies and bring them to the commercial market. If selected for SBIR funding, participants will be granted a royalty-free, non-exclusive patent license agreement for internal research use for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that they will develop the invention into a commercial product to benefit the public.

The NCI Intramural Research Program performs high quality and innovative research in a variety of basic, translational, and clinical areas that include: immunotherapy, imaging, diagnostics, cancer therapeutics, genetics/genomics, developmental biology, cellular and gene therapy, and cell and molecular biology related to cancer and the infectious diseases of HIV and AIDS. The SBIR Technology Transfer (SBIR-TT) program enables the grantee to license and commercialize an available NCI invention in any portfolio area. Another feature of the SBIR-TT Program is that the awardee may work closely with the NCI inventor(s), who can provide assistance during the award period.

Interested applicants should submit an SBIR application through grants.gov using the SF424(R&R) application package. Small businesses are encouraged to submit a license application to the technology transfer office of the participating institute before submitting an SBIR application. The SBIR application will be reviewed by the NIH Center for Scientific Review (CSR), while license applications will be reviewed by the institute's technology transfer office. Under the SBIR-TT program, the SBIR grant review process will be conducted in parallel with, but distinct from, the review of any application for a license.